Effects of an Omega-3 Fatty Acid-based Supplement on Healthy Ageing
Trial Parameters
Brief Summary
The goal of this randomised, double-blind placebo controlled trial is to explore tolerability and the effects of a new omega-3 fatty acid-based supplement on biological and clinical aspects relevant for healthy ageing. Participants will be asked to take a supplement or a placebo for 6 months, and to attend the clinic a total of 3 times and to perform or submit the following: * Physical examination * Muscle function tests * Cognitive testing * Questionnaire completion * Biological samples, including blood, saliva and faeces. Researchers will compare the results from the group taking the supplement to the results of the group taking a placebo to see if the supplement has an effect on biological and clinical aspects associated with healthy ageing.
Eligibility Criteria
Inclusion Criteria: * Aged 55 or more * BMI between 25-30, * Waist-to-hip ratio of at least 0.90 (males) or 0.85 (females) * Omega-3 index \<6 Exclusion Criteria: * Dementia * Current clinically significant depression, i.e. major depression or GDS 15 score \>7 * Ischemic or haemorrhagic Stroke * Acute myocardial infarction * Any form of clinically significant atherosclerotic cardiovascular disease * Unstable angina pectoris * Hearth failure in need of treatment * Diabetes mellitus type 1 or 2 * Clinically relevant kidney diseases that require dialysis, including clinically significant chronic kidney disease * Liver cirrhosis or active hepatitis B or C * Cancer of any kind; however, benign tumours are no exclusion criterium * Clinically relevant inflammatory or autoimmune disorders with history of hospitalisation * Any form of systemic lupus erythematosus (SLE), rheumatoid arthritis, Colitis ulcerosa, Crohn's disease, Morbus Parkinson, Multiple Sclerosis * hsCRP \> 3.0 mg/L to exclude h